ADDS

Research and development in the fields of pharmaceuticals, therapeutics, and biologics, namely, exosome-based delivery systems for pharmaceuticals, therapeutics, and biologics; Medical research and development in the field of molecular biology, genetic engineering, drug delivery, and bioinformatics; Research and development of delivery systems for therapeutic compounds, namely, exosome-based drug delivery systems for therapeutic compounds for the treatment of viral pathogens, cancer and inherited disorder in humans; Research and development of delivery systems for therapeutic compounds, namely, exosome-based drug delivery of therapeutic compounds; Research and development of delivery systems for therapeutic nucleic acids, namely, exosome-based drug delivery of therapeutic nucleic acids, namely, RNA; Research and development of delivery systems for therapeutic peptides, namely, exosome-based drug delivery of therapeutic peptides; Research and development of delivery systems for gene-editing proteins, namely, exosome-based drug delivery of gene-editing proteins; Research and development of delivery systems for vaccines, namely, exosome-based drug delivery systems for vaccines; Research and development of delivery systems for vaccines, namely, exosome-based drug delivery systems for pharmaceutical compounds; Research and development of the production of exosomes for therapeutic uses, namely, yeast-based exosome for therapeutic uses; Research and development of new biological products for therapeutic use; Design and development of nucleic acids, proteins, enzymes, and drug compounds for use in pharmaceuticals, biotechnology, medical, and diagnostic applications